Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

PURPOSE: Although durable responses can be achieved with tyrosine kinase inhibitors such as imatinib in melanomas harboring KIT mutations, the efficacy of alternative inhibitors after progression to imatinib and the activity of these agents on brain metastases is unknown. EXPERIMENTAL DESIGN: We con...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Carvajal, Richard D., Lawrence, Donald P., Weber, Jeffrey S., Gajewski, Thomas F., Gonzalez, Rene, Lutzky, Jose, O’Day, Steven J., Hamid, Omid, Wolchok, Jedd D., Chapman, Paul B., Sullivan, Ryan J., Teitcher, Jerrold B., Ramaiya, Nikhil, Giobbie-Hurder, Anita, Antonescu, Cristina R., Heinrich, Michael C., Bastian, Boris C., Corless, Christopher L., Fletcher, Jonathan A., Hodi, F. Stephen
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013827/
https://ncbi.nlm.nih.gov/pubmed/25695690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1630
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados